ArticleKidney international2025
Detection and characterization of NELL1 autoantibodies in NELL1 positive membranous nephropathy.
Article in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Ten tips for the diagnosis and management of nephrotic syndrome.Clinical kidney journal · 2026Review
- Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy.Kidney international · 2026Article
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- A membranous nephropathy variant mimicking minimal change disease.The journal of pathology. Clinical research · 2026Article
- Urinary betaine/creatinine ratio enhances diagnostic accuracy of PLA2R-Ab in idiopathic membranous nephropathy.BMC nephrology · 2025Article
- Questions and Caveats in Antigen-Defined Membranous Nephropathy.Journal of the American Society of Nephrology : JASN · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionDiscovery of novel autoantigens in membranous nephropathy provides promise for development of serologic tests to monitor disease activity and guide treatment. Neural epidermal growth factor-like 1 (NELL1) is the second leading antigen in membranous nephropathy, associated with malignancy, certain medications, and mercury poisoning. Anti-NELL1 antibodies are currently detected within patient sera by western blotting against NELL1 recombinant protein, but no high-throughput clinical assays are available.
methodsHere, we detail the development of a quantitative ELISA and an indirect immunofluorescence assay for detection of anti-NELL1 antibodies within patient sera and demonstrate that circulating anti-NELL1 antibodies are predominantly IgG1 and IgG4.
resultsThese assays had high specificity (94.9%-100%), but relatively low sensitivity (61.3%- 66.7%) compared to the reference standard, defined as biopsy-proven NELL1-positivity. ELISA demonstrated 83.9% overall agreement with the immunofluorescence assay and 82.8% with Western blot, compared to 72.4% overall agreement between the latter two assays.
conclusionsOur study provides methods for serologic testing to be utilized for serologic evaluation of NELL1-associated membranous nephropathy. Further work will establish if antibody titters correlate with disease activity and response to immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.